Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells $50,526.63 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Pascal Deschatelets sold 2,277 shares of the business’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $22.19, for a total value of $50,526.63. Following the completion of the sale, the insider directly owned 1,158,219 shares of the company’s stock, valued at $25,700,879.61. This represents a 0.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Apellis Pharmaceuticals Stock Performance

Shares of NASDAQ APLS opened at $19.94 on Friday. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.10 and a current ratio of 3.54. The firm has a market cap of $2.52 billion, a price-to-earnings ratio of 64.32 and a beta of 0.31. The business’s 50-day simple moving average is $22.89 and its 200-day simple moving average is $23.45. Apellis Pharmaceuticals, Inc. has a 52 week low of $16.10 and a 52 week high of $31.17.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Thursday, October 30th. The company reported $1.67 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.64. The firm had revenue of $458.58 million during the quarter, compared to analyst estimates of $364.58 million. Apellis Pharmaceuticals had a return on equity of 18.94% and a net margin of 4.43%.The company’s revenue for the quarter was up 133.0% on a year-over-year basis. During the same period in the previous year, the company earned ($0.46) EPS. As a group, equities research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Parallel Advisors LLC lifted its position in shares of Apellis Pharmaceuticals by 80.0% in the 2nd quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock worth $33,000 after acquiring an additional 855 shares during the period. Jones Financial Companies Lllp raised its stake in shares of Apellis Pharmaceuticals by 206.8% in the third quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock valued at $46,000 after purchasing an additional 1,373 shares in the last quarter. Osaic Holdings Inc. lifted its position in Apellis Pharmaceuticals by 141.2% in the second quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock worth $47,000 after purchasing an additional 1,570 shares during the period. Allworth Financial LP boosted its stake in Apellis Pharmaceuticals by 64.1% during the third quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock worth $50,000 after buying an additional 857 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in Apellis Pharmaceuticals in the 3rd quarter valued at $64,000. Institutional investors and hedge funds own 96.29% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on APLS shares. JPMorgan Chase & Co. dropped their target price on shares of Apellis Pharmaceuticals from $40.00 to $36.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Apellis Pharmaceuticals in a research report on Monday, December 29th. Wolfe Research assumed coverage on Apellis Pharmaceuticals in a research report on Thursday, November 6th. They set a “peer perform” rating for the company. TD Cowen decreased their target price on Apellis Pharmaceuticals from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Friday, October 31st. Finally, Citigroup dropped their price target on Apellis Pharmaceuticals from $52.00 to $45.00 and set a “buy” rating on the stock in a research report on Friday, October 31st. Eleven analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $33.65.

Key Apellis Pharmaceuticals News

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: Wells Fargo reiterated a Buy on Apellis, signaling continued confidence in the company’s longer‑term commercial execution and pipeline upside — a supportive voice for holders focused beyond near‑term sales. Read More.
• Positive Sentiment: Stifel Nicolaus issued a Buy on APLS (or reiterated constructive coverage), adding a second favorable analyst view that could help stabilize valuation if execution improves. Read More.
• Neutral Sentiment: Analysts remain mixed on Apellis: some see upside from Syfovre rollout and nephrology expansion while others emphasize near‑term sales risk and valuation — expect continued divergent research notes and volatile price reactions to company updates. Read More.
• Negative Sentiment: Apellis reported preliminary Q4 U.S. net product revenue of $190M and flagged weaker Syfovre sales with mixed Empaveli uptake — the main near‑term driver cited for a recent sharp weekly decline in the stock. Read More.
• Negative Sentiment: Major research houses (Cantor Fitzgerald, Needham) issued more pessimistic forecasts or lowered expectations, increasing downward pressure by reducing modeled revenues and price targets. Read More. Read More.
• Negative Sentiment: Significant insider selling on Jan. 13: multiple senior execs (CEO Cedric Francois, CFO Timothy Sullivan, General Counsel David Watson and others) sold shares at ~ $22.19 — filings show they still retain large stakes but the volume of disposals can be perceived negatively by the market. Read More.
• Negative Sentiment: Options flow indicated a large spike in put buying (reported >500% increase in put volume), reflecting elevated hedging and bearish positioning that can amplify short‑term volatility and downside pressure. Source: options flow reports

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.